{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T22:33:47Z","timestamp":1769639627859,"version":"3.49.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>A study of latent tuberculosis infection (LTBI) burden by chest roentgenography (CXR) with reference to interferon-gamma release assay (IGRA) is still lacking in rheumatic patients of an intermediate tuberculosis burden area.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We retrospectively reviewed clinical data of patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), or psoriatic arthritis (PsA) receiving LTBI screening for biologics from Jan 2013 to April 2014.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 238 rheumatic patients who underwent LTBI screening were included in this study, of whom 46 (19.3%) had positive IGRA tests, 178 (74.8%) had negative results, and 14 (5.9%) had indeterminate results. Radiological findings suggesting healed tuberculosis (CXR-old-TB) were found in 18.1% of all patients, 23.9% in the IGRA -positive patients vs 16.9% in the IGRA-negative patients (OR 1.55 95% CI: 0.71\u20133.39, <jats:italic>p<\/jats:italic>\u2009=\u20090.27). Forty (40\/46, 87.0%) IGRA-positive patients received isoniazid prophylaxis and 77.5% of them finished treatment. Six patients developed adverse effects of isoniazid treatment, resulting in an overall number needed to harm (NNH) of 6.7 (40\/6). IGRA-non-positive patients with old TB-suggestive CXR comprised 13.4% (32\/238) of all our rheumatic patients, and one of them developed pulmonary tuberculosis within one year after screening.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>LTBI disease burden in rheumatic patients is substantial according to the estimation of CXR and IGRA screening. Correlation between CXR and IGRA is not significant in rheumatic patients, which implies their complementary roles. IGRA-non-positive patients with old TB-suggestive CXR comprise a significant portion in rheumatic patients and merit cautious follow-up by rheumatologists, tuberculosis specialists, and pulmonologists.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12890-020-01274-9","type":"journal-article","created":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T12:03:04Z","timestamp":1598875384000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Chest roentgenography is complementary to interferon-gamma release assay in latent tuberculosis infection screening of rheumatic patients"],"prefix":"10.1186","volume":"20","author":[{"given":"Ping-Huai","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chou-Han","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting-Hui","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2815-1743","authenticated-orcid":false,"given":"Chien-Sheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,31]]},"reference":[{"issue":"22","key":"1274_CR1","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1056\/NEJMra1405427","volume":"372","author":"H Getahun","year":"2015","unstructured":"Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med. 2015;372(22):2127\u201335.","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"1274_CR2","doi-asserted-by":"publisher","first-page":"S189","DOI":"10.1086\/429994","volume":"41","author":"HM Algood","year":"2005","unstructured":"Algood HM, Lin PL, Flynn JL. Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Clin Infect Dis. 2005;41(Suppl 3):S189\u201393.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"1274_CR3","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1002\/art.11137","volume":"48","author":"JJ Gomez-Reino","year":"2003","unstructured":"Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003;48(8):2122\u20137.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"1274_CR4","first-page":"1436","volume":"30","author":"L Carmona","year":"2003","unstructured":"Carmona L, Hernandez-Garcia C, Vadillo C, Pato E, Balsa A, Gonzalez-Alvaro I, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol. 2003;30(7):1436\u20139.","journal-title":"J Rheumatol"},{"issue":"12","key":"1274_CR5","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.3899\/jrheum.150057","volume":"42","author":"JW Ai","year":"2015","unstructured":"Ai JW, Zhang S, Ruan QL, Yu YQ, Zhang BY, Liu QH, et al. The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-alpha antagonist: a metaanalysis of both randomized controlled trials and registry\/cohort studies. J Rheumatol. 2015;42(12):2229\u201337.","journal-title":"J Rheumatol"},{"issue":"5","key":"1274_CR6","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1183\/09031936.00028510","volume":"36","author":"I Solovic","year":"2010","unstructured":"Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J. 2010;36(5):1185\u2013206.","journal-title":"Eur Respir J"},{"issue":"1","key":"1274_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1378\/chest.11-3157","volume":"142","author":"R Diel","year":"2012","unstructured":"Diel R, Loddenkemper R, Nienhaus A. Predictive value of interferon-gamma release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. Chest. 2012;142(1):63\u201375.","journal-title":"Chest."},{"issue":"1","key":"1274_CR8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1164\/rccm.200402-232OC","volume":"170","author":"I Brock","year":"2004","unstructured":"Brock I, Weldingh K, Lillebaek T, Follmann F, Andersen P. Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. Am J Respir Crit Care Med. 2004;170(1):65\u20139.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"1274_CR9","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1164\/rccm.201006-0974OC","volume":"183","author":"R Diel","year":"2011","unstructured":"Diel R, Loddenkemper R, Niemann S, Meywald-Walter K, Nienhaus A. Negative and positive predictive value of a whole-blood interferon-\u03b3 release assay for developing active tuberculosis: an update. Am J Respir Crit Care Med. 2011;183(1):88\u201395.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"1274_CR10","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1378\/chest.08-2575","volume":"136","author":"L Richeldi","year":"2009","unstructured":"Richeldi L, Losi M, D'Amico R, Luppi M, Ferrari A, Mussini C, et al. Performance of tests for latent tuberculosis in different groups of immunocompromised patients. Chest. 2009;136(1):198\u2013204.","journal-title":"Chest."},{"issue":"11","key":"1274_CR11","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1136\/annrheumdis-2011-200408","volume":"71","author":"X Mariette","year":"2012","unstructured":"Mariette X, Baron G, Tubach F, Liot\u00e9 F, Combe B, Miceli-Richard C, et al. Influence of replacing tuberculin skin test with ex vivo interferon gamma release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy. Ann Rheum Dis. 2012;71(11):1783\u201390.","journal-title":"Ann Rheum Dis"},{"key":"1274_CR12","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/1471-2334-9-207","volume":"9","author":"EY Kim","year":"2009","unstructured":"Kim EY, Lim JE, Jung JY, Son JY, Lee KJ, Yoon YW, et al. Performance of the tuberculin skin test and interferon-gamma release assay for detection of tuberculosis infection in immunocompromised patients in a BCG-vaccinated population. BMC Infect Dis. 2009;9:207.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"1274_CR13","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/1756-185X.12188","volume":"17","author":"SV Navarra","year":"2014","unstructured":"Navarra SV, Tang B, Lu L, Lin HY, Mok CC, Asavatanabodee P, et al. Risk of tuberculosis with anti-tumor necrosis factor-alpha therapy: substantially higher number of patients at risk in Asia. Int J Rheum Dis. 2014;17(3):291\u20138.","journal-title":"Int J Rheum Dis"},{"key":"1274_CR14","unstructured":"Statistics report of annual TB incidence in Taiwan. https:\/\/daily.cdc.gov.tw\/stoptb\/caremagchart.aspx. Accessed Apr 20, 2019."},{"issue":"12","key":"1274_CR15","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.5588\/ijtld.13.0368","volume":"17","author":"WM Ke","year":"2013","unstructured":"Ke WM, Chen LS, Parng IM, Chen WW, On AW. Risk of tuberculosis in rheumatoid arthritis patients on tumour necrosis factor-alpha inhibitor treatment in Taiwan. Int J Tuberc Lung Dis. 2013;17(12):1590\u20135.","journal-title":"Int J Tuberc Lung Dis."},{"issue":"3","key":"1274_CR16","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1080\/03009742.2016.1202318","volume":"46","author":"YM Chiu","year":"2017","unstructured":"Chiu YM, Tang CH, Hung ST, Yang YW, Fang CH, Lin HY. A real-world risk analysis of biological treatment (adalimumab and etanercept) in a country with a high prevalence of tuberculosis and chronic liver disease: a nationwide population-based study. Scand J Rheumatol. 2017;46(3):236\u201340.","journal-title":"Scand J Rheumatol"},{"issue":"6","key":"1274_CR17","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1002\/art.21043","volume":"52","author":"L Carmona","year":"2005","unstructured":"Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, Montero D, Pascual-Gomez E, Mola EM, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. 2005;52(6):1766\u201372.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"1274_CR18","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.5588\/ijtld.12.0111","volume":"16","author":"N Saidenberg-Kermanac'h","year":"2012","unstructured":"Saidenberg-Kermanac'h N, Semerano L, Naccache JM, Brauner M, Falgarone G, Dumont-Fischer D, et al. Screening for latent tuberculosis in anti-TNF-\u03b1 candidate patients in a high tuberculosis incidence setting. Int J Tuberc Lung Dis. 2012;16(10):1307\u201314.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"8","key":"1274_CR19","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/1756-185X.12708","volume":"19","author":"F Cantini","year":"2016","unstructured":"Cantini F, Lubrano E, Marchesoni A, Mathieu A, Olivieri I, Salvarani C, et al. Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey. Int J Rheum Dis. 2016;19(8):799\u2013805.","journal-title":"Int J Rheum Dis"},{"issue":"6","key":"1274_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0178035","volume":"12","author":"CH Lim","year":"2017","unstructured":"Lim CH, Chen HH, Chen YH, Chen DY, Huang WN, Tsai JJ, et al. The risk of tuberculosis disease in rheumatoid arthritis patients on biologics and targeted therapy: a 15-year real world experience in Taiwan. PLoS One. 2017;12(6):e0178035.","journal-title":"PLoS One"},{"key":"1274_CR21","first-page":"1","volume":"29","author":"YH Chen","year":"2015","unstructured":"Chen YH, Su WJ, Hsieh SC, Yu KH, Wu Jan YJ, Lee CS, et al. 2015 TRA revised recommendations for screening and management of tuberculosis infection in patients before and after anti-tumor necrosis factor-alpha biological treatment. Formosan J Rheumatol. 2015;29:1\u20138.","journal-title":"Formosan J Rheumatol"},{"issue":"5","key":"1274_CR22","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/acr.21641","volume":"64","author":"JA Singh","year":"2012","unstructured":"Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625\u201339.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"1274_CR23","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1136\/thx.2005.046797","volume":"60","author":"British Thoracic Society Standards of Care Committee","year":"2005","unstructured":"British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax. 2005;60(10):800\u20135.","journal-title":"Thorax"},{"issue":"6","key":"1274_CR24","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s00408-014-9637-y","volume":"192","author":"T Targowski","year":"2014","unstructured":"Targowski T, Chelstowska S. T. P. IGRA as a predictive factor of silent pulmonary changes in individuals following exposure to tuberculosis. Lung. 2014;192(6):869\u201374.","journal-title":"Lung."},{"issue":"8","key":"1274_CR25","doi-asserted-by":"publisher","first-page":"e805","DOI":"10.1371\/journal.pone.0000805","volume":"2","author":"R Joshi","year":"2007","unstructured":"Joshi R, Patil S, Kalantri S, Schwartzman K, Menzies D, Pai M. Prevalence of abnormal radiological findings in health care workers with latent tuberculosis infection and correlations with T cell immune response. PLoS One. 2007;2(8):e805.","journal-title":"PLoS One"},{"key":"1274_CR26","first-page":"135","volume":"47","author":"P Steinbr\u00fcck","year":"1972","unstructured":"Steinbr\u00fcck P, D\u0103nkov\u00e3 D, Edwards LB, Doster B, Livesay VT. Tuberculosis risk in persons with \u201cfibrotic\u201d x-ray lesions. Bull Int Union Tuberc. 1972;47:135\u201359.","journal-title":"Bull Int Union Tuberc"},{"key":"1274_CR27","doi-asserted-by":"publisher","first-page":"S221","DOI":"10.1164\/ajrccm.161.supplement_3.ats600","volume":"161","author":"Targeted tuberculin testing and treatment of latent tuberculosis infection","year":"2000","unstructured":"Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med. 2000;161:S221\u201347.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"1274_CR28","doi-asserted-by":"publisher","first-page":"e93986","DOI":"10.1371\/journal.pone.0093986","volume":"9","author":"TS Hermansen","year":"2014","unstructured":"Hermansen TS, Thomsen VO, Lillebaek T, Ravn P. Non-tuberculous mycobacteria and the performance of interferon gamma release assays in Denmark. PLoS One. 2014;9(4):e93986.","journal-title":"PLoS One"},{"issue":"4","key":"1274_CR29","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","volume":"175","author":"DE Griffith","year":"2007","unstructured":"Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367\u2013416.","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"1274_CR30","first-page":"1136","volume":"11","author":"NN Linh","year":"2007","unstructured":"Linh NN, Marks GB, Crawford AB. Radiographic predictors of subsequent reactivation of tuberculosis. Int J Tuberc Lung Dis. 2007;11(10):1136\u201342.","journal-title":"Int J Tuberc Lung Dis."},{"key":"1274_CR31","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3899\/jrheum.140100","volume":"91","author":"R Piccazzo","year":"2014","unstructured":"Piccazzo R, Paparo F, Garlaschi G. Diagnostic accuracy of chest radiography for the diagnosis of tuberculosis (TB) and its role in the detection of latent TB infection: a systematic review. J Rheumatol Suppl. 2014;91:32\u201340.","journal-title":"J Rheumatol Suppl"},{"issue":"7","key":"1274_CR32","doi-asserted-by":"publisher","first-page":"761","DOI":"10.3346\/jkms.2012.27.7.761","volume":"27","author":"YJ Jeong","year":"2012","unstructured":"Jeong YJ, Yoon S, Koo HK, Lim HJ, Lee JS, Lee SM, et al. Positive tuberculin skin test or interferon-gamma release assay in patients with radiographic lesion suggesting old healed tuberculosis. J Korean Med Sci. 2012;27(7):761\u20136.","journal-title":"J Korean Med Sci"},{"key":"1274_CR33","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ijid.2016.11.006","volume":"56","author":"GJ Fox","year":"2017","unstructured":"Fox GJ, Dobler CC, Marais BJ, Denholm JT. Preventive therapy for latent tuberculosis infection-the promise and the challenges. Int J Infect Dis. 2017;56:68\u201376.","journal-title":"Int J Infect Dis"},{"issue":"180","key":"1274_CR34","doi-asserted-by":"publisher","first-page":"180ra149","DOI":"10.1126\/scitranslmed.3005260","volume":"5","author":"HL Mills","year":"2013","unstructured":"Mills HL, Cohen T, Colijn C. Community-wide isoniazid preventive therapy drives drug-resistant tuberculosis: a model-based analysis. Sci transl Med. 2013;5(180):180ra149.","journal-title":"Sci transl Med"},{"issue":"5","key":"1274_CR35","doi-asserted-by":"publisher","first-page":"744","DOI":"10.3201\/eid1205.050681","volume":"12","author":"ME Balcells","year":"2006","unstructured":"Balcells ME, Thomas SL, Godfrey-Faussett P, Grant AD. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis. 2006;12(5):744\u201351.","journal-title":"Emerg Infect Dis"},{"issue":"23","key":"1274_CR36","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","volume":"365","author":"TR Sterling","year":"2011","unstructured":"Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155\u201366.","journal-title":"N Engl J Med"},{"issue":"11","key":"1274_CR37","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1136\/annrheumdis-2018-213097","volume":"77","author":"YM Chen","year":"2018","unstructured":"Chen YM, Liao TL, Chen HH, Chen DY. Three months of once-weekly isoniazid plus rifapentine (3HP) in treating latent tuberculosis infection is feasible in patients with rheumatoid arthritis. Ann Rheum Dis. 2018;77(11):1688\u20139.","journal-title":"Ann Rheum Dis"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-020-01274-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-020-01274-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-020-01274-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T23:07:19Z","timestamp":1630364839000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-020-01274-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,31]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1274"],"URL":"https:\/\/doi.org\/10.1186\/s12890-020-01274-9","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,31]]},"assertion":[{"value":"22 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study was approved by the Institutional Review Board of Far Eastern Memorial Hospital (IRB-105066-E). Since this was a retrospective study, consent was waived.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare they have no competing interests regarding this study.and manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"232"}}